Cue Biopharma's immunology candidate meets endpoint in chronic hives study
Cue Biopharma reported that its experimental treatment for chronic spontaneous urticaria succeeded in a Phase 2 trial conducted in China. This marks the company's first clinical results since shifting its focus from oncology to immunology. The candidate is positioned as a potential competitor to Xolair, a standard therapy for the condition.
This announcement marks a notable pivot for Cue Biopharma, which has repositioned its pipeline toward immunology after previously concentrating on oncology. The positive Phase 2 result in chronic spontaneous urticaria—a condition characterized by persistent, unexplained hives—offers an early signal of efficacy in a large patient population. Because the trial was conducted in China, the data may also support a regional regulatory path. The candidate is being framed as a future alternative to Xolair, the current standard of care, though head-to-head comparisons and later-stage trials remain necessary.
If the candidate advances, it could broaden treatment options for people with chronic hives who do not respond adequately to existing therapies. Patients may benefit from a new mechanism of action, potentially reducing reliance on a single dominant drug. However, market impact depends on safety, dosing convenience, and pricing. Physicians and insurers may weigh these factors carefully, while investors will watch for confirmatory data. The shift toward immunology also reflects a wider industry trend of repurposing biologic platforms beyond oncology.